Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 months ago) | |
US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 months ago) | |
US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 months ago) | |
US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 months ago) | |
US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(3 years from now) | |
US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(5 years from now) | |
US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(7 years from now) | |
US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
ODE* (ODE*) | May 26, 2024 |
Market Authorisation Date: 18 March, 2019
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: TABLET;ORAL
87
United States
20
China
20
European Union
14
Spain
13
Australia
13
Japan
12
Brazil
12
Korea, Republic of
10
Denmark
10
Slovenia
10
Portugal
10
Cyprus
10
Poland
9
Mexico
9
Russia
8
Hong Kong
8
Argentina
8
Croatia
8
Canada
7
South Africa
7
Norway
7
Taiwan, Province of China
7
New Zealand
6
Israel
5
Singapore
5
Ecuador
5
EA
4
Austria
4
Morocco
4
Malaysia
4
Peru
4
RS
4
Tunisia
3
Lithuania
3
Hungary
3
Colombia
3
Iceland
3
San Marino
3
Chile
3
United Kingdom
3
Ukraine
2
Jordan
2
Germany
2
Guatemala
2
Yugoslavia
2
Georgia
2
ME
1
El Salvador
1
Cuba
1
Costa Rica
1
Honduras
1
Sweden
1
Netherlands
1
Dominican Republic
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic